Biological therapies, 3

Biomedical research, 21–22, 31

Blastocoel, 29–30, 115

Blastocysts, 1–2, 29–31, 34–36, 47–48, 66, 83, 115.

See also Mouse blastocysts

discarding, 10, 82

donors of, 4, 7–9, 57, 100, 106

excess, 42

implanting, 30

increasing the yield of, 36

produced by donor gametes used in IVF, 83, 101, 126

safe handling, storage, and transportation of, 4, 90, 101–102, 127

safeguards against misuse of, 4, 26

Bone marrow, 17, 115

Brown, Louise, 22

Bush, George H. W., 23

Bush, George W., 2, 18, 21

C

Cadaveric fetal tissue, derivation of stem cells from, 16–17

California Institute for Regenerative Medicine, 76

Canada, 78–79, 84

national body established in, 59

procurement practices in, 66

Canadian Assisted Human Reproduction Agency, 27

Canadian Institute for Health Research, 78

Cash payments, not offering to donors, 9–10, 85

Categories of research proposals, 7–8, 57–58, 98–99, 124–125

research not permissible at this time, 8, 57–58, 99, 124–125

research permissible after notification of the ESCRO committee, 7, 57, 99, 124

research permissible only after additional review and approval of the ESCRO committee, 7–8, 57, 124

Cell-based therapies, 20, 44

Cell lines

banking and distribution of, 92–95

ensuring sufficient genetic diversity among, 60, 125

Cells restricted to specific developmental fates, development of hES cells down particular pathways to generate, 43–44

CFR. See Code of Federal Regulations

CGTP. See Current good tissue practices

Chimeras, 6–8, 17, 30, 39–41, 116

preventing from breeding, 40, 55, 58, 106

Choice. See Autonomy

CLIA. See Clinical Laboratory Improvement Amendments

Clinical care. See Standards of clinical care

Clinical Laboratory Improvement Amendments (CLIA), 90

Clinton, William J., 20, 23

Cloning

of Dolly the sheep, 2, 16, 34

human reproductive, 5

producing abnormalities, 34

therapeutic, 19

Cloning-for-biomedical-research now, 21

Cloning Human Beings, 20

Code of Federal Regulations (CFR), 64–66, 68

Code of Practice for the Use of Human Stem Cell Lines, 52

Collaborations, substituting equivalent foreign procedures in, 58, 106, 125

Common Rule, 54n, 64n

Compliance

imposing sanctions to ensure, 14, 106–107

recommendations for, 11–12, 71, 126

with relevant FDA regulations, 74, 126

Confidentiality, 4, 56, 82

Conflict of interest, 107

Conscience, personnel objecting to hES cell research for reasons of, 11, 92, 102, 128

Consent. See Informed consent of donors

Contamination, concerns about, 18

Contraception, developing better techniques for, 77

Coriell, 93

“Council of Europe Recommendation R(97)5 on the Protection of Medical Data,” 74n

Cryopreserved embryos, 81

Culture conditions, not including mouse feeder cells and bovine serum, 43

Current good tissue practices (CGTP), 72

D

Department of Health, Education, and Welfare (DHEW), 22–23

Department of Health and Human Services (DHHS), 24, 54n, 64

Office for Human Research Protections, 65–67



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement